)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Verona Pharma
Verona Pharma (VRNA) investor relations material
Verona Pharma has been acquired by Merck & Co Inc
Verona Pharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary6 Aug, 2025
Executive summary
Entered into a $10 billion acquisition agreement with Merck, expected to close in Q4 2025, subject to customary approvals.
Ohtuvayre (ensifentrine) approved by FDA for COPD in June 2024; U.S. launch began August 2024.
Submitted marketing applications for Ohtuvayre in the UK and EU in mid-2025.
Net income of $11.9 million for Q2 2025, first profitable quarter; accumulated deficit $567.1 million as of June 30, 2025.
Ongoing dispute with Nuance Pharma over buy-back of Greater China license; discussions ongoing.
Financial highlights
Q2 2025 revenue: $103.1 million, driven by $102.9 million in Ohtuvayre product sales.
Six months ended June 30, 2025: $179.4 million total revenue, $174.2 million from product sales.
Q2 2025 operating income: $13.3 million, compared to a $68.4 million loss in Q2 2024.
Cash and cash equivalents: $438.0 million as of June 30, 2025, up from $399.8 million at year-end 2024.
Selling, general and administrative expenses rose to $72.1 million in Q2 2025, up $23.1 million year-over-year, mainly due to commercial launch costs and share-based compensation.
Outlook and guidance
Cash, anticipated product sales, and available term loan funding expected to cover operating and capital needs for at least 12 months.
Future term loan advances contingent on commercial milestones and lender discretion.
If Merck transaction does not close, may seek to license Ohtuvayre outside the U.S. and require additional funding.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Verona Pharma
- Early launch success, broad adoption, and new J-code set stage for strong 2024 growth.VRNA
Piper Sandler 36th Annual Healthcare Conference - Rapid adoption of a novel COPD therapy is fueling expansion and pipeline innovation.VRNA7th Annual Evercore ISI HealthCONx Conference
- Ohtuvayre's launch is outperforming peers, with strong growth and expanding market adoption.VRNAJefferies London Healthcare Conference 2024
- Ohtuvayre's U.S. launch drove $5.6M Q3 sales and rapid adoption, backed by strong cash reserves.VRNAQ3 2024
- Ohtuvayre launches as a novel COPD therapy, showing strong early adoption and future growth plans.VRNACanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024
- Ohtuvayre's U.S. launch saw rapid uptake, $70.8M Q2 loss, and $404.6M in cash reserves.VRNAQ2 2024
- FDA approved Ohtuvayre for COPD maintenance, launching Q3 2024 with broad support.VRNAFDA Announcement
- Ohtuvayre’s differentiated profile drives rapid COPD adoption, with growth set to accelerate through 2027.VRNAGoldman Sachs 46th Annual Global Healthcare Conference
- Ohtuvayre's rapid COPD uptake and robust pipeline signal strong future growth.VRNALeerink Global Healthcare Conference 2025
- Ohtuvayre's US launch drove 95% sequential sales growth and record Q1 revenue, with strong outlook.VRNAQ1 2025
Verona Pharma
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Verona Pharma plc is a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of respiratory diseases. Its main product, ensifentrine, is designed to alleviate symptoms and improve health outcomes in conditions such as chronic obstructive pulmonary disease (COPD). The company is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.